Early Release of HMGB1 may Aggravate Neuronal Damage after Transient Focal Ischemia in Diabetic Rat Brain

Naohiro Iwata¹, Mari Okazaki², Shinya Kamiuchi¹, Meiyan Xuan³, Hirokazu Matsuzaki², Takeshi Sakamoto³ and Yasuhide Hibino*¹

¹Laboratory of Immunobiochemistry, Department of Clinical Dietetics & Human Nutrition, Faculty of Pharmaceutical Sciences, Josai University, Japan
²Laboratory of Pharmacology, School of Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences, Josai University, Japan
³Laboratory of Organic and Medicinal Chemistry, School of Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences, Josai University, Japan

*Corresponding author: Yasuhide Hibino, Laboratory of Immunobiochemistry, Department of Clinical Dietetics & Human Nutrition, Faculty of Pharmaceutical Sciences, Josai University, 1-1 Keyakidai Sakado Saitama 350-0295, Japan, Tel: +81-49-271-7285, Fax: +81-49-271-7284, E-mail: seitaib@josai.ac.jp

Abstract

Objective: High Mobility Group Box 1 (HMGB1) released extracellularly from necrotic cells evokes delayed inflammatory processes via interaction with the Receptor for Advanced Glycation End Products (RAGE) or Toll-like Receptors (TLR) in postischemic brain. The diabetic state (DM) aggravated cerebral ischemic injury following the stroke in rats. Therefore, we examined the behavior of HMGB1 and the expression of RAGE in non-DM and DM rat brain after middle cerebral artery occlusion followed by reperfusion (MCAO/Re).

Methods: Diabetes was induced by a single injection of streptozotocin in male Sprague Dawley rats (DM group). MCAO/Re was performed in non-DM and DM rats (ischemic groups) using a standard intraluminal procedure, and postischemic neurological deficits. Both brain infarction and edema were evaluated at various times after reperfusion. Control non-DM and DM rats underwent sham operation using the same manipulation, but without insertion of the occlusion filament. The behavior of HMGB1 and the expression of its receptors in the rat brain were examined using immunohistochemical and western blot analyses.

Results: In sham-operated DM rat brain, immunoreactivity of HMGB1, which was localized in the neuronal nuclei of the cortex, was markedly increased compared with that in non-DM sham-operated rat brain. In the ischemic groups, the DM state aggravated MCAO/Re-induced neurological deficits and cerebral injury assessed by the infarction volume. Enhancement of translocation of HMGB1 from the nucleus to the cytoplasm induced by MCAO/Re was markedly accelerated in the penumbral region of DM rat cortex. Immunoblot analysis revealed that the ischemia-induced increase in the release of HMGB1 into the cerebrospinal fluid and plasma was also enhanced in DM rats. Moreover, the expression of RAGE was upregulated in the brains of DM ischemic and control rats.

Conclusions: The early release of HMGB1 and the expression of its receptors may be involved in the aggravation of neuronal damage caused by transient cerebral ischemia in DM rats. Therefore, it is important to inhibit the HMGB1 released in response to ischemia during the treatment of postischemic injury in diabetic patients.

Keywords

High-mobility group box 1 (HMGB1), Diabetes, Middle cerebral artery occlusion (MCAO), Brain injury, Receptor for advanced glycation end products (RAGE)

Introduction

Diabetes mellitus (DM), which causes chronic hyperglycemia and increases physiological oxidative stress, is a major risk factor for atherosclerotic diseases such as acute brain ischemia [1,2]. World Health Organization data show that about 386 million people worldwide are currently suffering from diabetes. Diabetic patients have a higher risk of stroke compared with nondiabetic patients, and they are more likely to have a poor prognosis and increased mortality after stroke [3,4]. Therefore, it is medically and socially important to reduce the complications of both diabetes and stroke. Previous studies have demonstrated that diabetes also increases oxidative stress in the brain and aggravates cerebral ischemic injury in the animal models [5-7]. In particular, hyperglycemia in the diabetic state increases the formation of reactive oxygen species (ROS) after reperfusion of the blood flow [8,9]. Furthermore, enhanced oxidative stress in the brain induced by diabetic hyperglycemia contributes to the exacerbation of the brain injury caused by transient ischemia [10,11].

High-mobility group box 1 (HMGB1) was first identified as a nonhistone chromosomal protein involved in DNA binding [12].
A few years later, it was isolated as a heparin-binding protein that promotes neurite outgrowth in rat brain and was called amphoterin [13,14]. In 1999, HMGB1 was recognized as a proinflammatory cytokine that mediates endotoxin lethality in mice [15], HMGB1 is highly conserved through evolution, and has 99% identity among all the mammals. Out of its 215 amino acids, only two residues are substituted in rodent and human versions [16]. HMGB1, a ubiquitous protein present in the nuclei of nearly all the cell types, can be actively secreted by different cell types, including activated monocytes and macrophages [15,17], mature dendritic cells [18], and endothelial cells [19]. Necrotic cells also release HMGB1 into the extracellular milieu, where it induces the expression of several genes related to inflammation, including tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), and leads to cell death [16,20]. In addition, this nuclear protein is endowed with extracellular signaling functions by interacting with different receptors such as the receptor for advanced glycation end products (RAGE) or toll-like receptor (TLR) 2 and TLR4 on the plasma membrane of various cell types [16,20].

RAGE, a transmembrane protein and a member of the immunoglobulin superfamily, is present on neurons, glia, and endothelial cells in the brain [21-24]. It interacts with various ligands, including HMGB1, advanced glycation end products (AGEs), β-amyloids, and S100 proteins [25]. In the cultured embryonic rat neuron, radiolabeled ligand binding studies with [125I] HMGB1 revealed that the binding affinity of HMGB1 to RAGE is seven-fold higher than HMGB1 to AGE, which was the first identified ligand for RAGE [26]. Interaction between RAGE and HMGB1 causes phosphorylation of mitogen-activated protein kinases (MAPKs; e.g., p38 and p42/44 kinases, stress-activated protein kinase/c-Jun N-terminal kinase, ERK1/2) and activation of the NF-κB signaling pathway in cultured macrophages, neutrophils, and Caco-2 epithelial cells [27,28]. This signaling is potentially linked to the receptor activation and is known to promote transcription of cytokines, such as TNF-α. Qiu et al. [29] found that HMGB1 treatment markedly increased the expression of the inflammatory mediators TNF-α, inducible nitric oxide synthase (iNOS) and intercellular adhesion molecule 1 (ICAM1) in the cultured glia and endothelial cells. They also reported the important participation of HMGB1 as a potential candidate in a specific upstream pathway promoting inflammation after brain ischemia [29]. Currently, the mechanism of interaction between HMGB1 and RAGE in the diabetic state is not well understood.

In the present study, we examined the relationship between the aggravation of cerebral ischemic injury following the stroke and the behavior of HMGB1 and its receptor, RAGE, in the diabetic rat brain after middle cerebral artery occlusion (MCAO) followed by reperfusion (MCAO/Re).

**Materials and Methods**

**Experimental diabetic animals**

Male Sprague Dawley rats (4 weeks old, weight 120–140 g; Sankyo Labo Service Co., Ltd., Tokyo, Japan) were housed two to a cage in a temperature-controlled environment (23 ± 0.5°C) with a 12-h light-dark cycle. The rats were given a standard rodent chow (CE-2; CLEA Japan, Inc., Tokyo, Japan) and water ad libitum. Animal care and surgical procedures were performed in accordance with the guidelines approved by the National Institutes of Health and the Josai University Animal Investigation Committee. A diabetic state was induced in the diabetic group (DM) rats by a single intraperitoneal injection of streptozotocin (STZ; 50 mg/kg) dissolved in 0.1 M sodium citrate (pH 4.5), while rats in the nondiabetic group (non-DM) were injected with buffer only [5]. Seven days after the STZ injection, a blood sample was collected by tail vein paracentesis and plasma glucose was determined using a glucose analyzer (Ascensia; Bayer Medical Co., Ltd., Land Nordrhein-Westfalen, Germany). Diabetes was defined as a blood glucose level >300 mg/dL. The DM and non-DM groups were each divided into two groups (ischemic and control) and were housed for an additional 6 weeks until stroke was induced by MCAO (ischemic groups) or a sham operation was performed (control groups).

**Middle cerebral arterial occlusion and reperfusion**

In the ischemic groups, MCAO was performed using a standard intraluminal procedure as previously described [5,30]. The rats were anesthetized with halothane (induction: 4%; maintenance: 1.5%) in 30% oxygen, using a face mask. Rectal temperature was maintained at 37°C with a heat lamp and a heating pad during the operation. A midline incision was made in the neck and the right common carotid artery was exfoliated under an operating microscope. All the branches of external carotid artery were ligated and isolated. The tips of 4-0 surgical nylon monofilaments were rounded by flame heating, and the rounded tips were inserted up through the internal carotid artery. Insertion was stopped when a small resistance was felt. Successful occlusion of the right middle carotid artery was confirmed when the left forelimb became flaccid after the nylon filament was introduced.

The distance from bifurcation of the common carotid artery to the tip of the suture was approximately 20 mm in all the rats. After occlusion for 2 h, the filament was withdrawn to allow for reperfusion. Cerebral blood flow was measured using Laser Doppler Flowmetry (ATBF-LCI; Unique Medical, Tokyo, Japan). There was an approximately 50% reduction in the baseline cerebral blood flow following MCAO. The animals were permitted to recover from the anesthesia at room temperature. The rats were sacrificed at 0.25, 0.5, 1, 3, 6, 12, 24, 48, and 72 h after reperfusion and the samples of brain and plasma were collected. The control groups underwent a sham operation with the same manipulation but without introduction of the monofilament.

**Neurological evaluation**

Postischemic neurological deficits were evaluated 2 h after MCAO, and 24 h after reperfusion using a 5-point scale as follows: grade 0, no deficit; grade 1, failure to extend right forepaw fully; grade 2, spontaneous circling or walking to the contralateral side; grade 3, walking only when stimulated; grade 4, unresponsive to stimulation and a depressed level of consciousness; and grade 5, death [5]. The rats that did not show neurological deficits were excluded from the study.

**Infarct and edema assessment**

At 0.25, 0.5, 1, 3, 6, 12, 24, 48, and 72 h after reperfusion, the rats were deeply anesthetized with halothane and decapitated. The brain was removed and cut into four 2mm coronal sections using a rat brain matrix, and was stained with 2% 2,3,5-triphenyltetrazolium chloride (TTC; Wako Pure Chemical Industries, Ltd., Osaka, Japan) at 37°C for 15 min. The coronal slices were fixed in 10% formaldehyde for 3 days before photography. Infarct areas were determined using an image analysis system (Scion Image 1.62; Scion Corporation, Frederick, MD, USA), and were integrated to obtain the infarct volumes per brain. The total infarct volume was calculated by adding all cross-sectional areas multiplied by 2 mm (thickness of the sections). Correction of the infarct volume for edema was achieved using the following equation: corrected infarct volume (%) = [left hemisphere volume − (right hemisphere volume − the infarct volume)]/left hemisphere volume × 100. Edema in the ischemic hemisphere was also calculated: edema (%) = (right hemisphere volume − the infarct volume)/left hemisphere volume × 100 [5].

**Evaluation of HMGB1 mRNA expression by real-time RT-PCR analysis**

The rats subjected to MCAO were sacrificed at 1, 3, 6, 12, 24, 48, or 72 h after reperfusion. Brains were quickly removed, placed in RNA later (QIAGEN, Hilden, Germany) and stored at −80°C until further processing. A total RNA sample was obtained from the ischemic penumbral cortex of each rat. Analysis of the gene expression of HMGB1 was conducted using quantitative real-time reverse transcriptase polymerase chain reaction (RT-PCR) as previously described [10,11,31]. In brief, the total RNA was extracted from the ipsilateral cortex with an RNAeasy Mini Kit (QIAGEN) accordingly.
to the manufacturer’s instructions. Total RNA (0.5 μg) from each sample was reverse-transcribed with oligo (dT) and random hexamer primers using reverse transcriptase (PrimeScript™ RT Enzyme Mix I, Takara RNA PCR Kit; Takara Biomedicals, Shiga, Japan). Real-time PCR was performed with 10 ng of cDNA and a pair of target gene specific primers (Takara Biomedicals) added to the SYBR Premix EX Taq (Takara Biomedicals) and subjected to PCR amplification in an iCycler iQ Real-Time Detection System (Bio-Rad Laboratories, Inc., Hercules, CA, USA; 1 cycle at 95°C for 10 s, and 50 cycles at 95°C for 5 s, and 60°C for 34 s). The expression of β-actin was used to normalize cDNA levels. The PCR products were analyzed by a melting curve to ascertain the specificity of amplification. The Primer sets were as follows: Hmgb1 (forward: GGAATAATAGCGAGGTTCGTGTTGG and reverse: CTGACATAGACAACTGGAAGATGG), β-actin (forward: GGAGATTACCTGCTGCTTCA and reverse: GACTCATCGACTCCTGTGCTG). The ratios of HMGBl normalized to β-actin were considered as the expression of HMGBl gene. All groups were compared to a nondiabetic-sham value of 1.

Immunohistochemistry

Immunohistochemical staining was performed as previously described [29,32]. In brief, the rats were sacrificed at the indicated time points and transcardially perfused with cold saline. Brains were fixed with 4% phosphate-buffered paraformaldehyde. Coronal brain sections (8 μm thick) were incubated sequentially with 3% hydrogen peroxide at room temperature for 40 min to inhibit endogenous peroxidase, followed by incubation with blocking buffer (4% Block Ace; Dainippon Sumitomo Pharma Co. Ltd., Osaka, Japan) for 2 h. The slides were incubated with polyclonal rabbit anti-HMGBl antibody (1:500, ab18256; Abcam Biotechnology, Cambridge, UK), polyclonal goat anti-RAGE antibody (1:200, sc-8230; Santa Cruz Biotechnology, CA, USA), monoclonal mouse anti-Neuronal nuclei (NeuN) antibody (1:500, MAB377; Chemicon, Temecula, CA, USA), monoclonal mouse anti-ionized calcium-binding adaptor molecule 1 (Iba1) antibody (1:500, ab15690; Abcam), or monoclonal mouse anti-glial fibrillary acidic protein (GFAP) antibody (1:500, 556327; BD Pharmingen, Franklin Lakes, NJ, USA) in 0.01 mol/l phosphate-buffered saline (PBS) at 4°C overnight. After washing with PBS, the slides were incubated with Cy3-conjugated donkey anti-rabbit IgG antibody (1:100, AP182C; Chemicon), Cy3-conjugated donkey anti-goat IgG antibody (1:100, AP180C; Chemicon) and FITC-conjugated goat anti-mouse IgG antibody (1:100, 81-6511; Zymed Laboratories, San Francisco, CA, USA) at room temperature for 2 h. Nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich, St. Louis, MO, USA), HRP-conjugated goat anti-rabbit IgG antibody (1:5,000, NA934; Amersham Biosciences), HRP-conjugated donkey anti-goat IgG antibody (1:5,000, sc-2020; Santa Cruz), and HRP-conjugated sheep anti-mouse IgG antibody (1:10,000, NA931; Amersham Biosciences). Immunoblotted bands were quantified using Image Gauge software (Fujifilm, Tokyo, Japan) after densitometric scanning of the films.

Statistical analysis

Data are presented as means ± S.D. Statistical analyses of mRNA levels and the area of cerebral damage were performed using a two-way ANOVA and post hoc Tukey’s multiple comparison tests. Neurological deficit scores were analyzed using the Kruskal–Wallis test followed by the Mann–Whitney U test. In all the cases, a P value of < 0.05 was taken as the level of significance.

Results

Postischemic neurological deficits were evaluated 2 h after MCAO and at various time points after reperfusion. There was no significant difference between non-DM (1.06 ± 0.23) and DM (0.96 ± 0.68) groups in the neurological deficit score 2 h after MCAO. However, after reperfusion, DM ischemic rats had significantly higher neurological deficit scores compared with those of non-DM ischemic rats. Death as a result of severe ischemic damage occurred in DM rats 48 h after reperfusion (Figure 1). There was no significant difference in regional cerebral blood flow among DM and non-DM ischemic groups and DM and non-DM controls (data not shown).

Representative coronal brain sections of non-DM and DM ischemic rats at various time points after MCAO/Re were stained with TTC. Intact areas of the tissue stain with deep red originating from mitochondrial activity of the living cells, while infarcted tissue stains pale pink. The brain injury induced by MCAO/Re was considerably exacerbated by the diabetic state. In DM ischemic rats, the cerebral infarcts were produced within 30 min of reperfusion and the infarct regions extended to the whole thalamus during 12 h after reperfusion. In non-DM ischemic rats, only the small striatal infarcts were observed 12 h after reperfusion. The infarct volume in DM ischemic rats 6 h after reperfusion was significantly larger (about 10.8-fold) compared with that in non-DM ischemic rats (Figure 2A,2B). Brain edema was also exacerbated by the diabetic state.
Figure 2: Brain infarct and edema in non-DM and DM ischemic rats detected by TTC staining

(A) Images of representative coronal brain sections from non-DM and DM rats stained by TTC at various time points after MCAO/Re showing viable (red) and dead (pale pink) tissues. Scale bar=5 mm. (B) Infarct volume (C) Edema in the ischemic hemispheres of non-DM and DM rats after MCAO/Re assessed by TTC staining. Data are presented as means ± SD (n=3–5 per time point). *p<0.01 vs. corresponding values for non-DM rats.

Figure 3: Expression of HMGB1 mRNA in the penumbral cortex of non-DM and DM ischemic rats following MCAO/Re, relative to expression in sham-operated non-DM rats

The expression level of HMGB1 mRNA was determined by real-time PCR analysis in the penumbral cortex after MCAO/Re. Sham operation involved the same manipulation but without insertion of the occlusive filament, as described in Materials and Methods. Data are presented as means ± SD (n=3–4 per time point).
However, the difference between non-DM and DM ischemic rats was not significant (Figure 2A,2C).

The level of HMGB1 mRNA in the total RNA from ischemic penumbral cortices was determined by real-time PCR. No apparent differences in the temporal expression pattern of HMGB1 were observed between non-DM and DM ischemic rats. HMGB1 gene expression was not affected by the cerebral ischemia during the 24 h after reperfusion, and was gradually reduced 48 h after reperfusion in the non-DM ischemic rats (Figure 3).

Localization of HMGB1 in sham-operated (control) non-DM and DM rat cortical neurons was determined by immunohistochemical staining and confocal imaging. To determine whether neurons, microglia, and/or astrocytes express HMGB1, colocalization experiments with specific neuronal, microglial, and astrocytic markers were performed. HMGB1 (red) was widely expressed throughout the brain. Nuclear localization of HMGB1 was confirmed by counterstaining with DAPI (blue) and colocalized with NeuN (green). However, neither of the control groups showed colocalization with GFAP (green) or IBA1 (green). Translocation of HMGB1 from the nucleus to the cytoplasm was observed in DM but not in non-DM control rats (Figure 4A,4B). Therefore, we focused on the localization of HMGB1 in the nerve cells.

Translocation of HMGB1 from the nucleus to the cytoplasm in the neuronal cells induced by MCAO/Re in non-DM ischemic rats was detected during 6 or 12 h after reperfusion. A large amount of HMGB1 was observed in the cytoplasm even in sham-operated DM

---

Figure 4: Immunohistochemical staining of HMGB1 in the penumbral cortex of sham-operated and ischemic non-DM and DM rats

Localization of HMGB1 was assessed using immunohistochemical staining of the penumbral cortex of (A) non-DM and (B) DM rats, 24 h after MCAO/Re. Immunohistochemical staining of HMGB1 (red) was merged with DAPI (blue), NeuN (green), GFAP (green), and IBA1 (green). Sham-operation involved the same manipulation but without the insertion of the occlusive filament, as described in Materials and Methods. Scale bar=20 μm

(A) non-DM (sham)

(B) DM (sham)
(A) HMGB1 / NeuN

DM  non-DM

sham 1 h 3 h 6 h 12 h

MCAO/Re

(B) HMGB1 / DAPI

DM  non-DM

sham 1 h 1 h

core penumbra

Merge

Figure 5: Translocation of HMGB1 in the penumbral cortex of sham-operated and ischemic non-DM and DM rats

Localization of HMGB1 was assessed using immunohistochemical staining of the penumbral cortex of non-DM and DM rats at various times after MCAO/Re. Immunohistochemical staining of HMGB1 (red) was merged with (A) NeuN (green) or (B) DAPI (blue). Insets are higher magnification micrographs of the cells indicated by arrowheads. Sham-operation involved the same manipulation but without insertion of the occlusive filament, as described in Materials and Methods. Scale bar=20 μm

Figure 6: The early release of HMGB1 induced by MCAO/Re in DM ischemic rats

Localization of HMGB1 was assessed using immunohistochemical staining of the penumbral cortex of non-DM and DM ischemic rats 1 h after MCAO/Re. Immunohistochemical staining of HMGB1 (red) was merged with DAPI (blue). The broken lines indicate the border between the core ischemic area (right side) and the penumbra (left side). Sham-operation involved the same manipulation but without insertion of the occlusive filament, as described in Materials and Methods. Scale bar=50 μm

rats, and in DM ischemic rats. MCAO/Re accelerated the translocation of HMGB1 from the nucleus to the cytoplasm in the majority of the neurons from 3 h after reperfusion (Figure 5).

Immunohistochemical investigation showed a distinct border corresponding to the cortical peri-infarct region 1 h after MCAO/Re in DM ischemic rats. Immunoreactivity of HMGB1 disappeared in the core of the ischemic lesion after MCAO/Re in DM ischemic rats (Figure 6).

HMGB1 levels in CSF and plasma after MCAO/Re were
Figure 7: Temporal changes in cerebrospinal fluid and plasma HMGB1 after MCAO/Re or sham operation in non-DM and DM rats. HMGB1 in (A) CSF and (B) plasma was detected by western blotting at various times after MCAO/Re in non-DM and DM rats. Sham-operation involved the same manipulation but without insertion of the occlusive filament, as described in Materials and Methods.

Figure 8: Levels of RAGE in the penumbral cortex after MCAO/Re or sham operation in non-DM and DM rats. (A) RAGE was assessed using immunohistochemical staining of the cortex of non-DM and DM rats at various times after MCAO/Re. (B) Quantitative analysis of fluorescence intensity of RAGE in the penumbral cortex. (C) Western blot analysis of RAGE and β-actin from brain tissue was performed. Sham-operation involved the same manipulation but without insertion of the occlusive filament, as described in Materials and Methods. Scale bar=50 μm. Data are presented as means ± SD (n=5–8 per time point). *p<0.01 compared with the non-DM sham group. #p<0.01 compared with the DM-sham group.
determined by the western blot analysis. No difference in the expression of HMGB1 was observed between the sham-operated non-DM and DM rats. The amount of HMGB1 in the CSF of non-DM ischemic rats increased gradually during 12 h after reperfusion. In contrast, HMGB1 in the CSF of DM ischemic rats was significantly increased approximately 3-fold 1 h after reperfusion, compared with after 12 h of reperfusion in non-DM ischemic rats (Figure 7A). Furthermore, HMGB1 levels in the plasma of DM ischemic rats showed a biphasic increase during 24 h after reperfusion. In the DM ischemic rats, plasma HMGB1 initially increased 1 h after reperfusion, by about 10-fold compared with non-DM ischemic rats. A second increase occurred up to 24 h after reperfusion, by about 3-fold compared with non-DM ischemic rats. The plasma HMGB1 in non-DM ischemic rats increased gradually during 24 h after reperfusion (Figure 7B).

The expression of RAGE in the rat brain was determined by immunohistochemical and western blot analyses. The immunoreactivity of RAGE gradually increased in the penumbra cortex of non-DM ischemic rats after MCAO/Re. RAGE expression was upregulated in sham-operated DM rats and increased up to 12 h after reperfusion in DM ischemic rats. Similar changes were also observed in the western blot analysis (Figure 8A-8C).

Discussion

The importance of inflammatory response in the pathophysiology of ischemic stroke is generally recognized. HMGB1 has been identified as an early mediator of hemorrhage after acute lung injury [33] and hepatic injury after liver ischemia/reperfusion [34]. Recent evidence suggests that the inflammatory cytokine HMGB1 is an active mediator of ischemic brain injury [29]. Moreover, elevated levels of HMGB1 in the serum of human patients with cerebral infarction have also been reported [35]. Therefore, HMGB1 has been attracting attention as a potential diagnostic marker [36,37].

HMGB1 was identified as a ubiquitously expressed, abundant nonhistone DNA-binding protein, which stabilizes the nucleosome formation and facilitates gene transcription. HMGB1 protein can be actively released into the extracellular space by macrophages and monocytes [16,20]. It is also passively released by necrotic cells, although not by apoptotic cells, and it triggers inflammation [38]. Extracellular HMGB1 interacts with different receptors, such as RAGE or TLR2/4 receptors, and promotes inflammatory responses leading to NF-κB activation [16,39]. Furthermore, HMGB1 has been reported to show delayed and sustained induction in the postischemic brain [40]. Previously, we revealed that the STZ-induced diabetic state aggravates cerebral ischemic injury following transient cerebral ischemia in the rats [5,10,11]. However, the mechanisms exacerbating the ischemic injury of the diabetic brain have not been elucidated. Therefore, in the present study, we examined the relationship between the aggravation of cerebral ischemic injury following the stroke in the diabetic state and the behavior of HMGB1 and its receptor, RAGE, in the rat brain after MCAO/Re.

The diabetic state aggravated MCAO/Re-induced neurological deficits and cerebral injury, as assessed by infarction volume. In the present study, the diabetic model had a significantly greater lesion volume and edema caused by MCAO/Re than previously reported [10,11]. Furthermore, we revealed that the infarct volume increases as early as 0.5 to 1 h after reperfusion in DM rats. HMGB1 gene expression was not affected by the cerebral ischemia in DM or non-DM rats. Immunohistochemical studies revealed that HMGB1 localized in the nuclei of the neuronal cells in sham-operated non-DM rat cortex, and was translocated from the nucleus to the cytoplasm of the neuronal cells during 6 or 12 h after reperfusion following MCAO in non-DM ischemic rats. We show that neurons are the principal sources of HMGB1 release in the early stages of ischemic injury. However, the translocation of HMGB1 was observed even in the sham-operated DM rat cortex. Furthermore, during MCAO/Re in DM rats, HMGB1 rapidly disappeared from all the cells within the cortex ischemic core from 1 h after reperfusion. Immunoreactivity against HMGB1 disappeared in the ischemic core and increased in CSF during 1 h after reperfusion in DM rat, suggesting earlier release of HMGB1 from necrotic neurons in the diabetic state.

Temporal changes in HMGB1 levels in CSF and plasma, an index of HMGB1 release, were also determined by immunoblot analysis. No difference in the amount of HMGB1 in CSF was observed between the sham-operated non-DM and DM rats. HMGB1 in the CSF of DM ischemic rats was considerably increased during 1 h after reperfusion, whereas in non-DM ischemic rats, HMGB1 in the CSF increased gradually during 12 h after reperfusion. The levels of HMGB1 in the plasma paralleled levels in the CSF. These results suggest that HMGB1 is readily translocated from the nucleus to the cytoplasm of the neuronal cells and immediately released after transient cerebral ischemia in the diabetic state. It has been reported that recombinant HMGB1 treatment increases inflammatory mediator gene expression in the cultured cells [29]. Therefore, the data reported herein suggest that HMGB1 may participate as an early upstream initiator of inflammation.

The expression of RAGE was upregulated in sham-operated DM rats and stabilized within 12 h after reperfusion in DM ischemic rats. The hyperglycemic conditions found in diabetes contribute to enhanced generation of AGE. Therefore, increases in expression of RAGE may contribute to generation of AGE and induce free radical generation [41]. Interestingly, genetic RAGE deficiency and decoy receptor soluble RAGE are reported to be associated with reduced infarct size [42].

HMGB1 causes activation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and increased reactive oxygen species production in the neutrophils [43]. It also increases the expression of matrix metalloproteinase 9 (MMP9) and participates in the failure of the blood–brain barrier [44]. Therefore, it may contribute to the increased edema that is associated with the increased mortality from stroke [45]. Conceivably, increased expression of HMGB1 receptors after ischemia could enhance the reactivity of signaling by HMGB1 receptor interaction [31,46-48]. Therefore, it is important to inhibit the HMGB1 released in response to ischemia during the treatment of postischemic injury in the diabetic patients.

In conclusion, the diabetic state induces pro-inflammatory cytokines in the brain, conceivably via hyperglycemia and/or oxidative stress, accelerating intracellular translocation and the release of HMGB1 from the neuronal cells after ischemic injury. An increase in extracellular HMGB1 may further induce inflammatory responses and cellular necrosis in the ischemic penumbra, leading to aggravation of ischemic injury in the diabetic patients.

Acknowledgement

This study was supported by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (No. 23790750). The authors would like to thank Enago (www.enago.jp) for the English language review.

Ethical Statement

All experiments were performed in compliance with the Guiding Principles for the Care and Use of Laboratory Animals approved by the Japanese Pharmacological Society, and the guidelines were approved by the Ethics Committee on Animal Care and Animal Experimentation at Josai University (#H260272). The number of animals used was kept to the minimum necessary for meaningful interpretation of the data. Animal discomfort was also minimized.

References


